

USPTO PATENT FULL-TEXT AND IMAGE DATABASE

Home

Quick

Advanced

Pat Num

Help

Next List

Bottom

[View Cart](#)

09/577,48

Searching 1976 to present...

Results of Search in 1976 to present db for:

(((aerosol AND respiratory) AND (((insoluble OR soluble) OR solubility) OR in-soluble)) AND drug) AND (((((nanoparticle OR nanoparticulate) OR micron) OR microns) OR nanometer) OR nanometers)): 1083 patents.

Hits 1 through 50 out of 1083

Next 50 Hits

Jump To

Refine Search

aerosol and respiratory and (insoluble or soluble or so

PAT.
NO.

Title

- 1 [6,914,132](#) **T** [Compositions and methods for the therapy and diagnosis of lung cancer](#)
- 2 [6,911,434](#) **T** [Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds](#)
- 3 [6,908,623](#) **T** [Compositions and methods for enhancing receptor-mediated cellular internalization](#)
- 4 [6,906,178](#) **T** [Vanilloid receptor-2](#)
- 5 [6,905,688](#) **T** [Albumin fusion proteins](#)
- 6 [6,903,105](#) **T** [Sodium channel blockers](#)
- 7 [6,903,086](#) **T** [Alkoxycarbonylamino benzoic acid or alkoxycarbonylamino tetrazolyl phenyl derivatives as IP antagonists](#)
- 8 [6,902,743](#) **T** [Therapeutic treatment and prevention of infections with a bioactive material\(s\) encapsulated within a biodegradable-bio-compatible polymeric matrix](#)
- 9 [6,900,220](#) **T** [Quinazalone derivatives as alpha 1A/B adrenergic receptor antagonists](#)
- 10 [6,900,218](#) **T** [Pyruvate derivatives](#)
- 11 [6,900,201](#) **T** [N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors](#)
- 12 [6,899,875](#) **T** [Methods and compositions relating to CD39-like polypeptides and nucleic acids](#)
- 13 [6,897,306](#) **T** [3-heterocyclylpropanohydroxamic acids](#)
- 14 [6,897,223](#) **T** [Pyridine fused bicyclic metalloproteinase inhibitors](#)
- 15 [6,897,045](#) **T** [Adeno-associated virus vectors](#)
- 16 [6,896,906](#) **T** [Storage stable powder compositions of interleukin-4 receptor](#)

- 17 [6,894,148](#) **T** [Secreted and transmembrane polypeptides and nucleic acids encoding the same](#)
- 18 [6,893,628](#) **T** [Aerosol formulations containing P134a and particulate medicament](#)
- 19 [6,890,920](#) **T** [Quaternary ammonium compounds](#)
- 20 [6,890,901](#) **T** [Hyaluronic drug delivery system](#)
- 21 [6,890,518](#) **T** [Compositions of chemically modified insulin](#)
- 22 [6,884,872](#) **T** [Methods and compositions relating to CD39-like polypeptides and nucleic acids](#)
- 23 [6,884,842](#) **T** [Molecular compounds having complementary surfaces to targets](#)
- 24 [6,884,794](#) **T** [Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets](#)
- 25 [6,884,784](#) **T** [Diagnosis and management of infection caused by chlamydia](#)
- 26 [6,884,775](#) **T** [Methods and compositions for regulating skeletogenic formation](#)
- 27 [6,884,771](#) **T** [Angiotensin converting enzyme homolog and uses therefor](#)
- 28 [6,884,770](#) **T** [Methods and compositions for treating or preventing peripheral neuropathies](#)
- 29 [6,884,619](#) **T** [Inhibition of BEHAB cleavage and primary central nervous system \(CNS\) tumors](#)
- 30 [6,881,823](#) **T** [Human protein HFXJW48](#)
- 31 [6,881,584](#) **T** [Infrared thermography](#)
- 32 [6,878,807](#) **T** [Secreted and transmembrane polypeptides and nucleic acids encoding the same](#)
- 33 [6,878,806](#) **T** [Human secreted protein HTEEB42](#)
- 34 [6,874,507](#) **T** [System for effecting smoking cessation](#)
- 35 [6,872,546](#) **T** [Hyaluronan-binding proteins and encoding genes](#)
- 36 [6,872,393](#) **T** [Polyalkylene oxide-modified single chain polypeptides](#)
- 37 [6,869,591](#) **T** [Paramagnetic particles that provide improved relaxivity](#)
- 38 [6,869,551](#) **T** [Precipitation of solid particles from droplets formed using focused acoustic energy](#)
- 39 [6,867,204](#) **T** [Benzoxazine derivatives and uses thereof](#)
- 40 [6,867,183](#) **T** [Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith](#)
- 41 [6,866,871](#) **T** [Dry powders of metal-containing compounds](#)
- 42 [6,865,926](#) **T** [Method and apparatus for sample analysis](#)
- 43 [6,864,266](#) **T** [4-piperidinyl alkyl amine derivatives as muscarinic receptor antagonists](#)
- 44 [6,861,227](#) **T** [Antibodies to cytokine receptor common gamma chain like](#)
- 45 [6,858,710](#) **T** [Compositions and methods for the therapy and diagnosis of ovarian cancer](#)
- 46 [6,858,706](#) **T** [Polypeptide comprising the amino acid of an N-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof](#)
- 47 [6,858,615](#) **T** [Phenyl guanidine sodium channel blockers](#)
- 48 [6,858,614](#) **T** [Phenolic guanidine sodium channel blockers](#)
- 49 [6,858,407](#) **T** [Human leucine-rich repeat containing protein expressed predominately in small intestine, HLRSI1](#)
- 50 [6,858,199](#) **T** [High efficient delivery of a large therapeutic mass aerosol](#)

Help